| 摘要: |
| 慢性肾脏病相关性贫血是慢性肾脏病(chronic kidney disease,CKD)进展过程中形成的贫血,是CKD的重要临床表现,也是主要并发症之一.有关改善肾性贫血的新型制剂,如红细胞生成刺激因子(erythropoiesis-stimulating agents, ESAs)、促红细胞生成素受体激动剂等正在临床试验中.本文综述促进红细胞生成、改善贫血的新疗法,并讨论其治疗的主要机制和不良反应;结合患者临床需求,权衡潜在优势与治疗风险,制定相关方案指导临床治疗,纠正患者贫血,进而降低心血管事件风险,提高终末期肾病(end-stage renal disease, ESRD)患者的生活质量. |
| 关键词: 肾疾病 贫血 铁调素 红细胞生成刺激因子 低氧诱导转录因子 |
| DOI：10.3724/SP.J.1008.2015.00776 |
| 投稿时间：2014-04-02修订日期：2015-02-13 |
| 基金项目: |
|
| Chronic kidney disease-associated anemia: progress in treatment |
| DAI De-shu,REN Hong-qi* |
(Department of Nephrology, Huaihai Hospital Affiliated to Xuzhou Medical College, Xuzhou 221000, Jiangsu, China
*Corresponding author) |
| Abstract: |
| Chronic kidney disease(CKD)-associated anemia is developed during CKD; it is one of the important clinical manifestations and complications of CKD. Presently some novel reagents to ameliorate anemia such as erythropoiesis-stimulating agents and erythropoietin receptor excitomotors, are in the process of clinical trials. In this paper we reviewed the novel remedies for correcting anemia and stimulating erythropoiesis; we also discussed the primary mechanisms and adverse effects of the treatment. The clinical treatment should be chosen according to the advantages and risks of each individual patients, so as to correct anemia, reduce risk of cardiovascular events, and eventually improve the life quality of patients with end-stage renal disease. |
| Key words: kidney diseases anemia hepcidin erythropoiesis-stimulating agents hypoxia-inducible factor |
